Bioline Launches the Full Range of EPIK(TM) miRNA Assays
January 09 2017 - 12:17PM
CINCINNATI, Jan. 09, 2017 (GLOBE
NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of
Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the
expansion of the EPIK(TM) miRNA Select Assays, originally developed
for the study of individual microRNA (miRNA) molecules. In
collaboration with MiRXES, Bioline released 800 EPIK(TM) miRNA
Select Assays in March 2016 and this has now been increased to
include all of the organisms listed on the miRBase release 21,
which represents over 27,000 miRNA assays. Recent studies continue
to show the clinical value of individual miRNA molecules which are
released from tissues and cells. The expression of certain
individual miRNA molecules correlates with specific disease
conditions making them promising biomarker candidates for the early
detection of disease, prognosis and monitoring of treatment in both
humans and other organisms.
Each assay is designed by
MiRXES in silico using proprietary
thermodynamics-based algorithms and include miRNA specific reverse
transcriptase primers and hemi-nested real-time PCR primers along
with Bioline reverse transcriptase, SensiSMART(TM) with
SYBR®1 Green and highly optimized buffers. The resulting
assays enable detection of extremely low levels of miRNA with very
high specificity and allow the discrimination between closely
related miRNA sequences.
Marco Calzavara, President of
Bioline commented, "I am very pleased to announce the expansion of
the EPIK miRNA Select Assays. The increased portfolio of high
quality miRNA assays will help even more researchers with miRNA
expression profiling, quantification and in biomarker
discovery."
Richard L. Eberly, President,
Chief Commercial Officer, stated, "The release of the full range of
EPIK miRNA Select Assays and their enhanced performance are an
important addition to our portfolio. They increase the flexibility
of this highly useful research tool by allowing more of our life
science customers to create accurate and non-invasive molecular
diagnostic assays in humans and in other organisms."
About
Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops,
manufactures, markets and distributes a broad range of innovative
diagnostic test kits, rare reagents, specialty biologicals and
components. Utilizing a variety of methods, our diagnostic tests
provide accuracy, simplicity and speed in the early diagnosis and
treatment of common medical conditions, such as infections and lead
poisoning. Meridian's diagnostic products are used outside of the
human body and require little or no special equipment. The
Company's diagnostic products are designed to enhance patient
well-being while reducing the total outcome costs of health care.
Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections and blood lead
level testing. In addition, Meridian is a supplier of rare
reagents, specialty biologicals and components used by
organizations in the life science and agribio industries engaged in
research and by companies as components in the manufacture of
diagnostics. The Company markets its products and technologies to
hospitals, reference laboratories, research centers, diagnostics
manufacturers and agribio companies in more than 70 countries
around the world. The Company's shares are traded on the NASDAQ
Global Select Market, symbol VIVO. Meridian's website address
is www.meridianbioscience.com.
FOR ADDITIONAL
INFORMATION:
For more information about Bioline, please
visit http://www.bioline.com.
__________________________________________
1 SYBR is a registered trademark of Thermo Fisher
Scientific.
CONTACT:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
rick.eberly@meridianbioscience.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Meridian Bioscience, Inc. via Globenewswire
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Mar 2023 to Mar 2024